- 2023 revenue rises 16 per cent to £56mn
- Adjusted cash profit up 44 per cent to £13mn
- Net cash of £37mn (5.4p)
- 90 per cent order book coverage for 2024
- Final dividend of £1.4mn (0.2p)
Aim-traded hVIVO (HVO:28.5p), a fast-growing contract research organisation (CRO), reported results slightly ahead of the upgraded guidance at the time of the pre-close trading update (‘Business is booming at Hvivo’, 12 February 2024).
The company provides early clinical development services for a broad client base of biopharma companies. It is the only CRO focused on human challenge studies, providing expertise and capabilities in challenge agent manufacturing, and has a portfolio of human challenge models to test a range of infectious and respiratory disease products.